Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Why the SARS-CoV-2 antibody test results may be misleading: insights from a longitudinal analysis of COVID-19

Jorg Taubel, Samuel Thomas Cole, Christopher S. Spencer, Anne Freier, Dorothée Camilleri, Ulrike Lorch
doi: https://doi.org/10.1101/2020.12.08.20245894
Jorg Taubel
1Richmond Research Institute, 1a Newcomen Street, London, SE1 1YR, UK
2Richmond Pharmacology Ltd, 1a Newcomen Street, London, SE1 1YR, UK
3St. George’s, University of London, Cranmer Terrace, Tooting, London, SW17 0RE, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: j.taubel@richmondpharmacology.com
Samuel Thomas Cole
2Richmond Pharmacology Ltd, 1a Newcomen Street, London, SE1 1YR, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher S. Spencer
1Richmond Research Institute, 1a Newcomen Street, London, SE1 1YR, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Freier
1Richmond Research Institute, 1a Newcomen Street, London, SE1 1YR, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorothée Camilleri
2Richmond Pharmacology Ltd, 1a Newcomen Street, London, SE1 1YR, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrike Lorch
2Richmond Pharmacology Ltd, 1a Newcomen Street, London, SE1 1YR, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

To estimate the effectiveness of vaccines in development, a robust mechanism is required to understand immunity, risks of reinfection and measure the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and how this may change over time. This study is a longitudinal analysis of COVID-19 infection rates using PCR, membrane immunoassay and chemiluminescent microparticle immunoassay (CMIA) diagnostic tests. Our data confirm that antibody levels wane in the three months after symptom onset. Comparison of the three methods used suggests that quantitative CMIA testing may exaggerate numbers of COVID-19 negative individuals.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

IRAS ID: 281788

Funding Statement

No external funding was received.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This brief report communicates results taken from a study reviewed and given favourable opinion by NRES Committee (West Midlands - Edgbaston).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Introduction/discussion sections updated to discuss recent papers on the COVID vaccine

Data Availability

Data available upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 11, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Why the SARS-CoV-2 antibody test results may be misleading: insights from a longitudinal analysis of COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Why the SARS-CoV-2 antibody test results may be misleading: insights from a longitudinal analysis of COVID-19
Jorg Taubel, Samuel Thomas Cole, Christopher S. Spencer, Anne Freier, Dorothée Camilleri, Ulrike Lorch
medRxiv 2020.12.08.20245894; doi: https://doi.org/10.1101/2020.12.08.20245894
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Why the SARS-CoV-2 antibody test results may be misleading: insights from a longitudinal analysis of COVID-19
Jorg Taubel, Samuel Thomas Cole, Christopher S. Spencer, Anne Freier, Dorothée Camilleri, Ulrike Lorch
medRxiv 2020.12.08.20245894; doi: https://doi.org/10.1101/2020.12.08.20245894

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (47)
  • Cardiovascular Medicine (416)
  • Dentistry and Oral Medicine (70)
  • Dermatology (49)
  • Emergency Medicine (146)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4875)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (678)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (633)
  • Health Policy (322)
  • Health Systems and Quality Improvement (208)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5362)
  • Intensive Care and Critical Care Medicine (332)
  • Medical Education (94)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (690)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (127)
  • Occupational and Environmental Health (209)
  • Oncology (443)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (90)
  • Pain Medicine (35)
  • Palliative Medicine (17)
  • Pathology (130)
  • Pediatrics (196)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (782)
  • Public and Global Health (1823)
  • Radiology and Imaging (325)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)